Navigation Links
Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 10, 2007 - Valeant Pharmaceuticals International (NYSE:VRX) announced today the publication of Phase 2 data for retigabine, a first-in-class neuronal potassium channel opener, in Neurology, a leading independent, scientific journal. The authors concluded that retigabine was efficacious with a demonstrated reduction in monthly seizure rates in this study. Two pivotal Phase 3 trials (RESTORE1 and RESTORE2) are currently underway to further investigate the efficacy and safety of retigabine as an adjunctive treatment for partial-onset seizures in patients with refractory epilepsy.

"There is a clear need for the development of antiepileptic drugs with new mechanisms of action to improve the management of patients whose epilepsy is not controlled by current medications," said Phase 2 study investigator and lead author Roger J. Porter, M.D., University of Pennsylvania. "This new molecule clearly acts by way of a different neuronal mechanism and if approved, would meet a market need. The Phase 2 data published in Neurology indicate that retigabine was efficacious for these hard-to-treat partial seizures in this study."

"We are pleased that these important findings have been published in Neurology," said Wesley P. Wheeler, president, North America and research and development. "Valeant is committed to developing innovative drugs for neurological disorders. We believe that potassium-channel openers with their unique mechanisms of action will advance the treatment of epilepsy."

In the study, investigators found that during the 8-week dose-escalation and 8-week maintenance periods, the addition of retigabine 600, 900 or 1,200 mg per day significantly reduced median monthly seizure frequency compared to baseline by 23, 29 and 35 percent, respectively. The reductions in the 900 and 1,200 mg groups were significantly greater than in the placebo group (13 percent vs. base
'"/>




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company ... to follow it on Facebook, Twitter, and Pinterest. The fans ... Angelweddingdress draws a lottery every week. , Moreover, the company ... 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... Colorado (PRWEB) January 22, 2015 Four years since ... Queen – which coincided with the marriage of Avasa & Matthew ... THE ROAD, which is scheduled for release through White Swan Records ... message that there is a sacred path available to all of ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... -- Cold and flu season is upon us,affecting tens ... to,the Centers for Disease Control. A cold is rarely ... and the elderly. Early detection,is key, especially since new ... infection,s onset., (Photo: http://www.newscom.com/cgi-bin/prnh/20080129/NYTUFNS1 ), ...
... BROOK, Ill. A novel treatment for blood clots in ... a pilot study published in the February issue of Radiology. ... a fiber-binding thrombolytic agent effectively treats deep vein thrombosis (DVT) ... This treatment regimen is able to clear blood clots rapidly ...
... WASHINGTON, Jan. 28 New reports released,today by the ... describe aggressive efforts by states in the past year ... their families, but,the actions may be curtailed as a ... effect., A downturn in the economy, the federal ...
... Idaho, Jan. 28 NightHawk,Radiology Holdings, Inc. (Nasdaq: ... to radiology groups across the United States, today ... ended December 31,2007. Results are subject to completion ... Preliminary 2007 Results, The company expects to ...
... to Properly Care for Both their Body ,Engine, and Vehicle ... ... Jiffy Lube today announces its,first-ever, nationwide cause-related campaign to support the American ... disease. Throughout February and March, 1,823 Jiffy Lube service,centers, more than 80 ...
... A team of Penn State University researchers is the ... relative importance of factors that contribute to DNA mutations, ... disorders. Led by assistant professor of biology Kateryna ... factors that are thought to increase the susceptibility to ...
Cached Medicine News:Health News:Flu and Fever Detection Facts for Dr. Mom 2Health News:Flu and Fever Detection Facts for Dr. Mom 3Health News:New therapy effectively treats deep vein thrombosis 2Health News:States Promoted Broader Coverage for Children in 2007, But Report That a Declining Economy Coupled With Lack of SCHIP Reauthorization and New Federal Rules Now Compromise Efforts to Reduce the Number of Uninsured 2Health News:States Promoted Broader Coverage for Children in 2007, But Report That a Declining Economy Coupled With Lack of SCHIP Reauthorization and New Federal Rules Now Compromise Efforts to Reduce the Number of Uninsured 3Health News:NightHawk Radiology Holdings, Inc. Announces Preliminary 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Announces Preliminary 2007 Results 3Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 2Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 3Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 4Health News:Jiffy Lube(R) Aims to Raise $1 Million for American Heart Association's Go Red For Women(TM) Movement 5Health News:Scientists explore factors contributing to DNA mutations 2Health News:Scientists explore factors contributing to DNA mutations 3Health News:Scientists explore factors contributing to DNA mutations 4
... The ProtecPoint Exit Alerting ... (e.g. patients, staff) and assets ... exit controllers placed throughout your ... exit protection, you're quickly ensured ...
... the movement of controlled substances, critical ... done. VerdaSee's "intellishelvess" are designed to ... is possible with no human intervention. ... this possible. VerdaSee Intellishelf™ product solutions ...
Agility can facilitate bed and room management through business process optimization using RFID technology. Bed and room management may be integrated with other AgileTrac products....
Assetrac allows identification, location, and protection of your assets....
Medicine Products: